| Literature DB >> 12185362 |
Sanne Weijzen1, Paola Rizzo, Mike Braid, Radhika Vaishnav, Suzanne M Jonkheer, Andrei Zlobin, Barbara A Osborne, Sridevi Gottipati, Jon C Aster, William C Hahn, Michael Rudolf, Kalliopi Siziopikou, W Martin Kast, Lucio Miele.
Abstract
Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild-type Notch signaling in neoplastic transformation remains unclear. Ras signaling is deregulated in a large fraction of human malignancies and is a major target for the development of novel cancer treatments. We show that oncogenic Ras activates Notch signaling and that wild-type Notch-1 is necessary to maintain the neoplastic phenotype in Ras-transformed human cells in vitro and in vivo. Oncogenic Ras increases levels and activity of the intracellular form of wild-type Notch-1, and upregulates Notch ligand Delta-1 and also presenilin-1, a protein involved in Notch processing, through a p38-mediated pathway. These observations place Notch signaling among key downstream effectors of oncogenic Ras and suggest that it might be a novel therapeutic target.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12185362 DOI: 10.1038/nm754
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440